Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...

Dominique McShain, who was diagnosed with colorectal cancer at the age of 20 and given just 1 - 5 years to live, wants to ...

The evidence is clear - screening for colorectal cancer may save one's life. Today, more and more people are choosing colorectal cancer screening. As a result, there is a steady decline in the number ...

A recent study published in the Journal of Cancer Research and Clinical Oncology explored genetic predictors of prostate cancer progression to help identify its clinical outcomes.

Kim Newcomer, director of volunteers, Colorectal Cancer Alliance, shares findings from a survey on colorectal cancer care ...

A new blood-based test could diagnose pancreatic cancer much earlier, improving outcomes for people with the disease.

What are the signs and symptoms of bladder cancer, and what are its risk factors? Here's what you need to know, according to an expert.

Colorectal cancer (CRC) is one of the most prevalent types of cancer and has a high mortality rate globally. Oral ...

Luminescent gold nanoparticles (L-AuNPs) represent a novel class of luminescent nanomaterials that have attracted ...

Based on work Dr. Petrylak presented at ASCO 2024 looking at dose adjustment and efficacy of enfortumab vedotin, most ...

Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...

The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...